A novel metabotropic glutamate receptor 5 positive allosteric modulator acts at a unique site and confers stimulus bias tomGlu5 signaling

Molecular Pharmacology

Volumn 83, Issue 4, 2013, Pages 835-847

  Noetzel, M J ^a   Gregory, K J ^c   Vinson, P N ^a   Manka, J T ^b   Stauffer, S R ^b   Lindsley, C W ^b   Niswender, C M ^a   Xiang, Z ^a   Conn, P J ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; GLUTAMIC ACID; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR AGONIST; N [4 CHLORO 2 ((4 FLUORO 1,3 DIOXOISOINDOLIN 2 YL)PHENYL]PICOLINAMIDE; UNCLASSIFIED DRUG;

ALLOSTERISM; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN SLICE; CALCIUM SIGNALING; CELL ASSAY; DRUG BINDING; DRUG BINDING SITE; DRUG EFFECT; DRUG SELECTIVITY; FEMALE; HIPPOCAMPUS; HUMAN; HUMAN CELL; LONG TERM DEPRESSION; LONG TERM POTENTIATION; MALE; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SUBTHALAMIC NUCLEUS;

ALLOSTERIC REGULATION; ANIMALS; BENZAMIDES; BINDING SITES; CELLS, CULTURED; FEMALE; HEK293 CELLS; HUMANS; MALE; PHTHALIMIDES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, METABOTROPIC GLUTAMATE; SIGNAL TRANSDUCTION;

EID: 84875416160     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.112.082891     Document Type: Article

References (41)

1. Auerbach BD, Osterweil EK, and Bear MF (2011) Mutations causing syndromic autism define an axis of synaptic pathophysiology. Nature 480:63-68.
2. Awad H, Hubert GW, Smith Y, Levey AI, and Conn PJ (2000) Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. J Neurosci 20:7871-7879.
3. Ayala JE, Chen Y, Banko JL, Sheffler DJ, Williams R, Telk AN, Watson NL, Xiang Z, Zhang Y, and Jones PJ et al. (2009) mGluR5 positive allosteric modulators facilitate both hippocampal LTP and LTD and enhance spatial learning. Neuropsychopharmacology 34:2057-2071.
4. Bradley SJ, Langmead CJ, Watson JM, and Challiss RA (2011) Quantitative analysis reveals multiple mechanisms of allosteric modulation of the mGlu5 receptor in rat astroglia. Mol Pharmacol 79:874-885.
5. Chen Y, Goudet C, Pin JP, and Conn PJ (2008) N-4-Chloro-2-[(1,3-dioxo-1, 3-dihydro- 2H-isoindol-2-yl)methyl]phenyl-2-hydroxybenzamide (CPPHA) acts through a novel site as a positive allosteric modulator of group 1 metabotropic glutamate receptors. Mol Pharmacol 73:909-918.
6. Chen Y, Nong Y, Goudet C, Hemstapat K, de Paulis T, Pin JP, and Conn PJ (2007) Interaction of novel positive allosteric modulators of metabotropic glutamate receptor 5 with the negative allosteric antagonist site is required for potentiation of receptor responses. Mol Pharmacol 71:1389-1398.
7. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
8. Conn PJ, Christopoulos A, and Lindsley CW (2009) Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov 8:41-54.
9. Fazio F, Lionetto L, Molinaro G, Bertrand HO, Acher F, Ngomba RT, Notartomaso S, Curini M, Rosati O, and Scarselli P et al. (2012) Cinnabarinic acid, an endogenous metabolite of the kynurenine pathway, activates type 4 metabotropic glutamate receptors. Mol Pharmacol 81:643-656.
10. Goudet C, Gaven F, Kniazeff J, Vol C, Liu J, Cohen-Gonsaud M, Acher F, Prézeau L, and Pin JP (2004) Heptahelical domain of metabotropic glutamate receptor 5 behaves like rhodopsin-like receptors. Proc Natl Acad Sci USA 101:378-383.
11. Gregory KJ, Dong EN, Meiler J, and Conn PJ (2011) Allosteric modulation of metabotropic glutamate receptors: structural insights and therapeutic potential. Neuropharmacology 60:66-81.
12. Gregory KJ, Noetzel MJ, Rook JM, Vinson PN, Stauffer SR, Rodriguez AL, Emmitte KA, Zhou Y, Chun AC, Felts AS, Chauder BA, Lindsley CW, Niswender CM and Conn PJ (2012) Investigating mGlu5 allosteric modulator cooperativity, affinity and agonism: enriching structure-function studies and structure-activity relationships. Mol Pharmacol 82:860-875.
13. Hammond AS, Rodriguez AL, Townsend SD, Niswender CM, Gregory KJ, Lindsley CW, and Conn PJ (2010) Discovery of a novel chemical class of mGlu(5) allosteric ligands with distinct modes of pharmacology. ACS Chem Neurosci 1:702-716.
14. Jung KM, Sepers M, Henstridge CM, Lassalle O, Neuhofer D, Martin H, Ginger M, Frick A, DiPatrizio NV, Mackie K, Katona I, Piomelli D and Manzoni OJ (2012) Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome. Nat Commun 3:1080.
15. Keov P, Sexton PM, and Christopoulos A (2011) Allosteric modulation of G proteincoupled receptors: a pharmacological perspective. Neuropharmacology 60:24-35.
16. Kinney GG, O'Brien JA, Lemaire W, Burno M, Bickel DJ, Clements MK, Chen TB, Wisnoski DD, Lindsley CW, and Tiller PR et al. (2005) A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models. J Pharmacol Exp Ther 313:199-206.
17. Lamb JP, Engers DW, Niswender CM, Rodriguez AL, Venable DF, Conn PJ, and Lindsley CW (2011) Discovery of molecular switches within the ADX-47273 mGlu5 PAM scaffold that modulate modes of pharmacology to afford potent mGlu5 NAMs, PAMs and partial antagonists. Bioorg Med Chem Lett 21:2711-2714.
18. Lazareno S and Birdsall NJ (1995) Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G proteincoupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors. Mol Pharmacol 48:362-378.
19. Leach K, Sexton PM, and Christopoulos A (2007) Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. Trends Pharmacol Sci 28: 382-389.
20. Liu F, Grauer S, Kelley C, Navarra R, Graf R, Zhang G, Atkinson PJ, Popiolek M, Wantuch C, and Khawaja X et al. (2008) ADX47273 [S-(4-fluoro-phenyl) -3-[3-(4- fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities. J Pharmacol Exp Ther 327:827-839.
21. Niswender CM and Conn PJ (2010) Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu Rev Pharmacol Toxicol 50:295-322.
22. Niswender CM, Johnson KA, Luo Q, Ayala JE, Kim C, Conn PJ, and Weaver CD (2008) A novel assay of Gi/o-linked G protein-coupled receptor coupling to potassium channels provides new insights into the pharmacology of the group III metabotropic glutamate receptors. Mol Pharmacol 73:1213-1224.
23. Niswender CM, Johnson KA, Miller NR, Ayala JE, Luo Q, Williams R, Saleh S, Orton D, Weaver CD, and Conn PJ (2010) Context-dependent pharmacology exhibited by negative allosteric modulators of metabotropic glutamate receptor 7. Mol Pharmacol 77:459-468.
24. Noetzel MJ, Rook JM, Vinson PN, Cho HP, Days E, Zhou Y, Rodriguez AL, Lavreysen H, Stauffer SR, and Niswender CM et al. (2012) Functional impact of allosteric agonist activity of selective positive allosteric modulators of metabotropic glutamate receptor subtype 5 in regulating central nervous system function. Mol Pharmacol 81:120-133.
25. O'Brien JA, Lemaire W, Wittmann M, Jacobson MA, Ha SN, Wisnoski DD, Lindsley CW, Schaffhauser HJ, Rowe B, and Sur C et al. (2004) A novel selective allosteric modulator potentiates the activity of native metabotropic glutamate receptor subtype 5 in rat forebrain. J Pharmacol Exp Ther 309:568-577.
26. Packiarajan M, Mazza Ferreira CG, Hong SP, White AD, Chandrasena G, Pu X, Brodbeck RM, and Robichaud AJ (2012) N-Aryl pyrrolidinonyl oxadiazoles as potent mGluR5 positive allosteric modulators. Bioorg Med Chem Lett 22:5658-5662.
27. Peavy RD and Conn PJ (1998) Phosphorylation of mitogen-activated protein kinase in cultured rat cortical glia by stimulation of metabotropic glutamate receptors. J Neurochem 71:603-612.
28. Pisani A, Gubellini P, Bonsi P, Conquet F, Picconi B, Centonze D, Bernardi G, and Calabresi P (2001) Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-aspartate responses in medium spiny striatal neurons. Neuroscience 106:579-587.
29. Popkirov SG and Manahan-Vaughan D (2011) Involvement of the metabotropic glutamate receptor mGluR5 in NMDA receptor-dependent, learning-facilitated long-term depression in CA1 synapses. Cereb Cortex 21:501-509.
30. Rodriguez AL, Grier MD, Jones CK, Herman EJ, Kane AS, Smith RL, Williams R, Zhou Y, Marlo JE, and Days EL et al. (2010) Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity. Mol Pharmacol 78:1105-1123.
31. Rodriguez AL, Nong Y, Sekaran NK, Alagille D, Tamagnan GD, and Conn PJ (2005) A close structural analog of 2-methyl-6-(phenylethynyl)-pyridine acts as a neutral allosteric site ligand on metabotropic glutamate receptor subtype 5 and blocks the effects of multiple allosteric modulators. Mol Pharmacol 68:1793-1802.
32. Sharma S, Kedrowski J, Rook JM, Smith RL, Jones CK, Rodriguez AL, Conn PJ, and Lindsley CW (2009) Discovery of molecular switches that modulate modes of metabotropic glutamate receptor subtype 5 (mGlu5) pharmacology in vitro and in vivo within a series of functionalized, regioisomeric 2- and 5-(phenylethynyl)pyrimidines. J Med Chem 52:4103-4106.
33. Sharma S, Rodriguez AL, Conn PJ, and Lindsley CW (2008) Synthesis and SAR of a mGluR5 allosteric partial antagonist lead: unexpected modulation of pharmacology with slight structural modifications to a 5-(phenylethynyl) pyrimidine scaffold. Bioorg Med Chem Lett 18:4098-4101.
34. Sheffler DJ and Conn PJ (2008) Allosteric potentiators of metabotropic glutamate receptor subtype 1a differentially modulate independent signaling pathways in baby hamster kidney cells. Neuropharmacology 55:419-427.
35. Sheffler DJ, Wenthur CJ, Bruner JA, Carrington SJ, Vinson PN, Gogi KK, Blobaum AL, Morrison RD, Vamos M, and Cosford ND et al. (2012) Development of a novel, CNS-penetrant, metabotropic glutamate receptor 3 (mGlu3) NAM probe (ML289) derived from a closely related mGlu5 PAM. Bioorg Med Chem Lett 22:3921-3925.
36. Stauffer SR (2011) Progress toward positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGlu(5)). ACS Chem Neurosci 2:450-470.
37. Varnes JG, Marcus AP, Mauger RC, Throner SR, Hoesch V, King MM, Wang X, Sygowski LA, Spear N, and Gadient R et al. (2011) Discovery of novel positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5). Bioorg Med Chem Lett 21:1402-1406.
38. Vinson PN and Conn PJ (2012) Metabotropic glutamate receptors as therapeutic targets for schizophrenia. Neuropharmacology 62:1461-1472.
39. Wood MR, Hopkins CR, Brogan JT, Conn PJ, and Lindsley CW (2011) "Molecular switches" on mGluR allosteric ligands that modulate modes of pharmacology. Biochemistry 50:2403-2410.
40. Zhang Y, Rodriguez AL, and Conn PJ (2005) Allosteric potentiators of metabotropic glutamate receptor subtype 5 have differential effects on different signaling pathways in cortical astrocytes. J Pharmacol Exp Ther 315:1212-1219.
41. Zhao Z, Wisnoski DD, O'Brien JA, Lemaire W, Williams DL, Jr, Jacobson MA, Wittman M, Ha SN, Schaffhauser H, and Sur C et al. (2007) Challenges in the development of mGluR5 positive allosteric modulators: the discovery of CPPHA. Bioorg Med Chem Lett 17:1386-1391.